TriangleCUE-102 (NCT06917885)
CUE-102 trial for Recurrent Glioblastoma (NCT06917885). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with glioblastoma, an aggressive brain cancer, that has come back.
The idea: give CUE-102 by vein. CUE-102 is a fusion protein built to find immune T cells that recognize WT1, a protein found on many cancer cells, and give those cells a boost with interleukin 2.
The study looks at safety and the dose to recommend.
This phase 1 study plans 18 patients. At Dana-Farber Cancer Institute in Boston, David Reardon leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.